{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:25:13Z","timestamp":1793733913782,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA01667"],"award-info":[{"award-number":["P30 CA01667"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["NMRC\/TCR\/007-NCC\/2013"],"award-info":[{"award-number":["NMRC\/TCR\/007-NCC\/2013"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CSA-SI-MOH-001568"],"award-info":[{"award-number":["CSA-SI-MOH-001568"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["OFLCG24may-0028"],"award-info":[{"award-number":["OFLCG24may-0028"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA247975"],"award-info":[{"award-number":["R01CA247975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R50CA265307"],"award-info":[{"award-number":["R50CA265307"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015936","name":"Guangzhou University of Chinese Medicine International Institute for Translational Chinese Medicine","doi-asserted-by":"publisher","award":["2017B030314120"],"award-info":[{"award-number":["2017B030314120"]}],"id":[{"id":"10.13039\/501100015936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007038","name":"Lung Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473227"],"award-info":[{"award-number":["82473227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422001"],"award-info":[{"award-number":["82422001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303641"],"award-info":[{"award-number":["82303641"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241235"],"award-info":[{"award-number":["82241235"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020355","name":"Interdisciplinary Center for Analytics on the Nanoscale, University of Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010577"],"award-info":[{"award-number":["2023A1515010577"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012772"],"award-info":[{"award-number":["2025A1515012772"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020352","name":"Rexanna's Foundation","doi-asserted-by":"publisher","award":["1U54CA224065-01"],"award-info":[{"award-number":["1U54CA224065-01"]}],"id":[{"id":"10.13039\/100020352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.annonc.2025.09.140","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T17:57:11Z","timestamp":1760983031000},"page":"104-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study"],"prefix":"10.1016","volume":"37","author":[{"given":"M.M.","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-6209","authenticated-orcid":false,"given":"F.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-1114","authenticated-orcid":false,"given":"A.C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.R.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Y.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-766X","authenticated-orcid":false,"given":"K.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-5641","authenticated-orcid":false,"given":"M.","family":"Borgeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-319X","authenticated-orcid":false,"given":"S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6712-5196","authenticated-orcid":false,"given":"E.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-980X","authenticated-orcid":false,"given":"H.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-9334","authenticated-orcid":false,"given":"J.W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2060-3584","authenticated-orcid":false,"given":"A.A.","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ringsurongkawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-176X","authenticated-orcid":false,"given":"Q.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.Z.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Y.C.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-0828","authenticated-orcid":false,"given":"A.","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.annonc.2025.09.140_bib1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.140_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.140_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.09.140_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.140_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.140_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400443","article-title":"Survival of patients with lung adenocarcinoma diagnosed in 2000, 2010, and 2020","volume":"4","author":"Debieuvre","year":"2025","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.140_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.140_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11864-012-0206-4","article-title":"Treatment of leptomeningeal spread of NSCLC: a continuing challenge","volume":"13","author":"Nagpal","year":"2012","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.140_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41571-024-00970-3","article-title":"Leptomeningeal metastatic disease: new frontiers and future directions","volume":"22","author":"Ozair","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.140_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaoncol.2024.2640","article-title":"Lazertinib in EGFR-variant non-small cell lung cancer with CNS failure to prior EGFR tyrosine kinase inhibitors: a nonrandomized controlled trial","volume":"10","author":"Hong","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.140_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11060-023-04483-4","article-title":"Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis","volume":"165","author":"Hong","year":"2023","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.140_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207959","article-title":"Prognostic role of ventricular size and its dynamics in patients with leptomeningeal metastasis from solid tumors","volume":"102","author":"Le Rhun","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.140_bib14","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.140_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11060-024-04616-3","article-title":"Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers","volume":"167","author":"Nakagawa","year":"2024","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.140_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/neuonc\/noz208","article-title":"A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer","volume":"22","author":"Nevel","year":"2020","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2025.09.140_bib17","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.09.140_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107475","article-title":"Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis","volume":"188","author":"Wu","year":"2024","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.140_bib20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.09.140_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2019.03.015","article-title":"A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases","volume":"131","author":"Yin","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.140_bib22","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.09.140_bib23","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.09.140_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.140_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.140_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamaoncol.2022.7364","article-title":"Assessment of phase 3 randomized clinical trials including patients with leptomeningeal disease: a systematic review","volume":"9","author":"Sharma","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.09.140_bib27","article-title":"Phase II study of lorlatinib in patients with anaplastic lymphoma kinase-positive lung cancer and CNS-specific relapse","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Pan","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.09.140_bib29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1078-0432.CCR-21-2733","article-title":"Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice","volume":"28","author":"Le","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.09.140_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.1600","article-title":"1286P Activity of tepotinib in brain metastases (BM): preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC","volume":"31","author":"Viteri","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.09.140_bib31","article-title":"Abstract CT082: capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)","volume":"80","author":"Garon","year":"2020","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2025.09.140_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2025.09.140_bib33","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib34","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","article-title":"Leptomeningeal metastases from solid tumors: a Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions","volume":"26","author":"Wilcox","year":"2024","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.140_bib35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jtho.2019.01.007","article-title":"Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC","volume":"14","author":"Zheng","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.140_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtho.2020.10.008","article-title":"Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC","volume":"16","author":"Zheng","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.140_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41591-025-03538-5","article-title":"Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases","volume":"31","author":"Zheng","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.140_bib38","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41591-025-03633-7","article-title":"RANO criteria for response assessment of brain metastases based on amino acid PET imaging","volume":"31","author":"Albert","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.09.140_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchins","year":"1987","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.140_bib41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.140_bib42","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.annonc.2025.09.140_bib43","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2025.09.140_bib44","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results","volume":"29","author":"Glitza","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.annonc.2025.06.001","article-title":"Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases","volume":"36","author":"Wilcox","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.09.140_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29668","article-title":"Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: a systematic review and meta-analysis","volume":"10","author":"Bian","year":"2024","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.annonc.2025.09.140_bib47","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1038\/s41591-025-03744-1","article-title":"Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial","volume":"31","author":"Preusser","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.09.140_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/neuonc\/noac180","article-title":"Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis","volume":"25","author":"Oberkampf","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.09.140_bib49","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S1470-2045(21)00488-5","article-title":"Leveraging external data in the design and analysis of clinical trials in neuro-oncology","volume":"22","author":"Rahman","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:26:26Z","timestamp":1778765186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425049312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0923753425049312"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.140","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.09.140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}